The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000810314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
26/05/2026
Date registered
Help: Date registered
7/07/2026
Date last updated
Help: Date last updated
7/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness and Health Economics of Acupuncture as a Symptom Cluster Intervention (ASC) During Breast Cancer Survivorship
Scientific title
Effectiveness and Health Economics of Acupuncture as a Symptom Cluster Intervention During Breast Cancer Survivorship
Additional trial identifiers [1] 317398 0
NIL
Universal Trial Number (UTN)
Trial acronym
ASC
Related trial records

Health condition
Health condition(s) studied:
breast cancer 342063 0
Condition category
Condition code
Cancer 338161 338161 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Acupuncture, eight 40 minute treatments across 8 weeks, and 4 weeks follow up. Stainless steel, single use needles will be used. Delivered individually and face to face by Australian Health Practitioner Regulation Agency (AHPRA) registered acupuncturists. Needle sites will be personalised using a semi-standardised protocol based on a manualisation guide and Traditional Chinese Medicine diagnosis by the attending acupuncturist. Delivered at outpatient clinic/hospital setting. Attendance to scheduled acupuncture appointments will be recorded for monitoring adherence.
Intervention code [1] 334196 0
Treatment: Other
Description of the comparator or control
Control group will receive usual care for the duration of the intervention period (12 weeks). Usual care is defined as continuing with the care they were receiving prior to enrolment. This is the care recieved from the participant's oncologist, surgeon, primary physician, and may include education and medication in relation to assisting with the management of their cancer and wellbeing. After the intervention period, the control will receive a modified acupressure guide of a protocol designed for symptom clusters during breast cancer survivorship.
Control group
Active

Outcomes
Primary outcome [1] 345542 0
symptom cluster score
Timepoint [1] 345542 0
baseline (week 0), mid intervention (week 4), end of intervention (week 8), follow up (week 12)
Secondary outcome [1] 462108 0
MDASI severity score (mean)
Timepoint [1] 462108 0
baseline (week 0), mid intervention (week 4), end of intervention (week 8), follow up (week 12)
Secondary outcome [2] 462109 0
quality of life
Timepoint [2] 462109 0
baseline (week 0), mid intervention (week 4), end of intervention (week 8), follow up (week 12)
Secondary outcome [3] 462110 0
health economics (cost utility)
Timepoint [3] 462110 0
baseline (week 0), mid intervention (week 4), end of intervention (week 8), follow up (week 12)
Secondary outcome [4] 462935 0
MDASI interference score (mean)
Timepoint [4] 462935 0
baseline (week 0), mid intervention (week 4), end of intervention (week 8), follow up (week 12)

Eligibility
Key inclusion criteria
- Diagnosed with breast cancer (excluding Ductal Carcinoma In Situ (DCIS))
- Over the age of 18
- Experience the symptom cluster
o At least 4 or more in a scale of 0-10 (Numeric rating scale)
o For 2 or more of the symptoms in the selected cluster (eg. hot flushes, memory concerns, pain, numbness/tingling)
- Able to commit to the study protocol
- Not currently undergoing neo/adjuvant chemotherapy or radiotherapy
o Breast cancer survivors who are on adjuvant endocrine therapy (AET) and long term (>3 months) maintenance immunotherapy, targeted therapy or combined therapy will be eligible to participate
- No plans for additional chemotherapy, radiotherapy, or other systemic therapy or surgery in the next 3 months
- Has been at least 4 weeks since the completion of chemotherapy or radiotherapy
- If on long term maintenance treatment, has been at least 4 weeks since commencement.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
- Has metastatic cancer
- Has recurrent cancer
- Pregnant
- Has thrombocytopenia ( <= 80)
- Has neutropenia
- Participating in another trial that addresses the symptoms in this cluster
- Started on pharmacological intervention for the symptoms in this cluster for less than 1 month
- Has received acupuncture in the last 2 weeks
- Participants with demand type pacemakers will be allowed to participate, but will be excluded from receiving electroacupuncture on the trunk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
computerized randomization and allocation using the randomization module on REDCap
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
1:1 allocation, variable block sizes 4 and 6, sequence generated by sealedenvelop.com
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321971 0
University
Name [1] 321971 0
Western Sydney University
Country [1] 321971 0
Australia
Funding source category [2] 322085 0
Hospital
Name [2] 322085 0
Chris O'Brien Lifehouse
Country [2] 322085 0
Australia
Funding source category [3] 322086 0
Hospital
Name [3] 322086 0
Mater Hospital
Country [3] 322086 0
Australia
Primary sponsor type
University
Name
Western Sydney University
Address
Country
Australia
Secondary sponsor category [1] 324850 0
Hospital
Name [1] 324850 0
Chris O'Brien Lifehouse
Address [1] 324850 0
Country [1] 324850 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320508 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 320508 0
Ethics committee country [1] 320508 0
Australia
Date submitted for ethics approval [1] 320508 0
19/02/2026
Approval date [1] 320508 0
Ethics approval number [1] 320508 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150698 0
Dr Suzanne Grant
Address 150698 0
NICM Health Research Institute, 158 Hawkesbury Rd, Westmead NSW 2145
Country 150698 0
Australia
Phone 150698 0
+61 02 8514 0038
Fax 150698 0
Email 150698 0
Contact person for public queries
Name 150699 0
Suzanne Grant
Address 150699 0
NICM Health Research Institute, 158 Hawkesbury Rd, Westmead NSW 2145
Country 150699 0
Australia
Phone 150699 0
+61 02 8514 0038
Fax 150699 0
Email 150699 0
Contact person for scientific queries
Name 150700 0
Suzanne Grant
Address 150700 0
NICM Health Research Institute, 158 Hawkesbury Rd, Westmead NSW 2145
Country 150700 0
Australia
Phone 150700 0
+61 02 8514 0038
Fax 150700 0
Email 150700 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.